Lexicon Pharmaceuticals, Inc.’s LXRX share price has surged by 7.25%, which has investors questioning if this is right time ...

Novo Nordisk is licensing Lexicon Pharmaceuticals' experimental obesity drug in a deal worth up to $1 billion, the Danish drugmaker's second deal this week, as it looks to strengthen the pipeline of ...

Lexicon Pharmaceuticals has a 52 week low of $0.28 and a 52 week high of $2.45. The firm has a market cap of $140.48 million, a price-to-earnings ratio of -0.76 and a beta of 1.04.

THE WOODLANDS, Texas — A Houston-area pharmaceutical company has struck a billion-dollar deal with the seller of Ozempic for a potential drug also aiming to combat obesity. Lexicon ...

During the last three months, 6 analysts shared their evaluations of Lexicon Pharmaceuticals (NASDAQ:LXRX), revealing diverse outlooks from bullish to bearish. The following table summarizes their ...

THE WOODLANDS, Texas, March 28, 2025 (GLOBE NEWSWIRE) -- Lexicon Pharmaceuticals, Inc. (Nasdaq: LXRX) today announced that it has entered into an exclusive license agreement with Novo Nordisk A/S ...

Lexicon Pharmaceuticals had a negative return on equity of 107.38% and a negative net margin of 4,109.41%. The firm had revenue of $26.55 million for the quarter, compared to analyst estimates of ...

The Danish pharmaceutical giant is licensing global rights to LX9851, a drug discovered and developed by Lexicon Pharmaceuticals, the companies announced Friday. LX9851 is an oral small molecule ...

Lexicon Pharmaceuticals, Inc. THE WOODLANDS, Texas, April 02, 2025 (GLOBE NEWSWIRE) -- Lexicon Pharmaceuticals, Inc. (Nasdaq: LXRX) today announced that Company management will participate in a ...

For Investor and Media Inquiries:Lisa DeFrancesco Lexicon Pharmaceuticals, [email protected] Source: Lexicon Pharmaceuticals, Inc. The views and opinions expressed herein are the views ...